Testing the PD-1 Antibody, MK3475, Given With Ziv-aflibercept in Patients With Advanced Cancer
National Cancer Institute (NCI)
National Cancer Institute (NCI)
M.D. Anderson Cancer Center
National Cancer Institute (NCI)
Dragonfly Therapeutics
Dana-Farber Cancer Institute
ViroMissile, Inc.
Pfizer
Tizona Therapeutics, Inc
MacroGenics
Fusion Pharmaceuticals Inc.
Innate Pharma
Novartis
M.D. Anderson Cancer Center
University Health Network, Toronto
NeoTX Therapeutics Ltd.
TScan Therapeutics, Inc.
Bolt Biotherapeutics, Inc.
Actym Therapeutics, Inc.
M.D. Anderson Cancer Center
Pfizer
Toray Industries, Inc
University of Virginia
Revolution Medicines, Inc.
Seagen Inc.
Sotio Biotech Inc.
Eli Lilly and Company
NGM Biopharmaceuticals, Inc
ADC Therapeutics S.A.
ABM Therapeutics Corporation
Pfizer
NGM Biopharmaceuticals, Inc
Celldex Therapeutics
Hefei TG ImmunoPharma Co., Ltd.
Adaptimmune
Sumitomo Pharma America, Inc.
Herlev Hospital
Quadriga Biosciences, Inc.
Novartis
Xencor, Inc.
Ludwig Institute for Cancer Research
Revolution Medicines, Inc.
Imperial College London
AbbVie
AbbVie
MacroGenics
Incyte Corporation
Mie University
Incyte Corporation
Seagen Inc.
Immune Design, a subsidiary of Merck & Co., Inc. (Rahway, New Jersey USA)